Arcutis Biotherapeutics
ARQT
24.17
+0.25
+1.05%
Arcutis Biotherapeutics
US · ARQT
#2465 by market cap
Listed 2020
24.17
+0.25
+1.05%
Live - 5344 symbols - heartbeat 346s ago
· 2026-10-08 07:15
Pre-market
24.22
+0.21%
After-hours
24.17
0.00%
- Market cap
- 3.04B
- P/E (TTM)i
- 109.86
- P/Bi
- 13.77
- EPSi
- -0.13
- Div yieldi
- 0.00%
- 52W posi
- 39%
Reader sentiment
Are you bullish or bearish on ARQT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 107.56% -0.15pp
- Institutions
- 336 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund58.37%
Hedge Fund26.52%
VC/PE Fund10.80%
Public Company7.07%
Private Company3.41%
Individual/Insider1.03%
Government Pension Fund0.71%
Sovereign Wealth Fund0.32%
Insurance Company0.31%
Top holders as of 2026-06-30
Montanova Capital, LLC
9.89% · 12.44M sh
BlackRock
8.39% · 10.55M sh
Frazier Life Sciences Management, LP
7.86% · 9.87M sh
Rubric Capital Management LP
6.58% · 8.27M sh
Polar Capital Holdings Plc
5.26% · 6.61M sh
State Street Global Advisors
4.63% · 5.82M sh
Vanguard Capital Management, LLC
4.62% · 5.80M sh
Morgan Stanley
3.49% · 4.39M sh
Jennison Associates LLC
3.36% · 4.22M sh
D. E. Shaw & Co., L.P.
3.14% · 3.95M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 18 buys · 31 sells
| Name | Role | Stake |
|---|---|---|
| Todd Watanabe | Chief Executive Officer | 0.51% |
| Christopher Peetz | Independent Director | 0.15% |
| Patrick Burnett | Senior VP & Chief Medical Officer | 0.09% |
| Latha Vairavan | Vice President of Finance & Investor Relations | 0.07% |
| Larry Edwards | Chief Commercial Officer | 0.05% |
| Patrick Heron | Independent Chairperson | 0.03% |
| Howard Welgus | Director | 0.02% |
| Masaru Matsuda | Senior Vice President | 0.02% |
| Keith Leonard | Independent Director | 0.01% |
| Halley Gilbert | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-15 | Masaru Matsuda | Senior Vice President | Open Market Disposition | -3,674 | $25.00 |
| 2026-09-14 | Howard Welgus | Director | Automatic Disposition | -634 | $24.18 |
| 2026-09-14 | Howard Welgus | Director | Derivative Exercise and Sale | -4,096 | $6.52–24.18 |
| 2026-09-07 | Masaru Matsuda | Senior Vice President | Automatic Disposition | -9,989 | $25.03 |
| 2026-08-26 | Terrie Curran | Independent Director | Derivative Exercise and Sale | -38,200 | $7.51–25.03 |
| 2026-08-19 | Terrie Curran | Independent Director | Derivative Exercise and Sale | -1,072 | $7.51–26.04 |
| 2026-08-18 | Patrick Burnett | Senior VP & Chief Medical Officer | Open Market Disposition | -1,697 | $27.00 |
| 2026-08-16 | Howard Welgus | Director | Automatic Disposition | -634 | $26.18 |
| 2026-08-16 | Howard Welgus | Director | Derivative Exercise and Sale | -4,096 | $6.52–26.18 |
| 2026-08-11 | Patrick Burnett | Senior VP & Chief Medical Officer | Derivative Exercise and Sale | -15,000 | $3.64–26.52 |
| 2026-08-02 | Todd Watanabe | Chief Executive Officer | Open Market Disposition | -4,375 | $26.12 |
| 2026-08-02 | Patrick Burnett | Senior VP & Chief Medical Officer | Open Market Disposition | -955 | $26.12 |
| 2026-08-02 | Masaru Matsuda | Senior Vice President | Open Market Disposition | -1,230 | $26.12 |
| 2026-07-14 | Howard Welgus | Director | Automatic Disposition | -634 | $26.91 |
| 2026-07-14 | Howard Welgus | Director | Derivative Exercise and Sale | -4,096 | $6.52–26.91 |
| 2026-07-14 | Christopher Peetz | Independent Director | Other Acquisition | +4,315 | -- |
| 2026-07-14 | Christopher Peetz | Independent Director | Other Derivative Acquisition | +34,496 | $27.78 |
| 2026-07-14 | Christopher Peetz | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-16 | Howard Welgus | Director | Automatic Disposition | -635 | $25.67 |
| 2026-06-14 | Howard Welgus | Director | Derivative Exercise and Sale | -4,096 | $6.52–24.41 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:15:25 · For reference only, not investment advice and not tailored to your situation.